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Detection of early esophageal squamous cell carcinoma (ESCC)
is very important, because these cancers can be treated with
minimally invasive endoscopic resection instead of surgery.
Early ESCC is characterized by subtle flat lesions, which are ea-
sily overlooked during routine white light endoscopy [1]. To im-
prove ESCC detection, the addition of Lugol iodine was intro-
duced [2]. Today, Lugol dye chromoendoscopy (LCE) is consid-
ered by many the gold standard for detection of early ESCC [3,
4].
Lugol iodine was first used in the esophagus to screen for
ESCC in 1966 [2]. In the esophagus, Lugol iodine binds to glyco-
gen [5]. Glycogen is diminished or absent in dysplastic or neo-
plastic tissue and abundant in normal squamous epithelium [5].
As a result, areas with dysplasia or neoplasia have reduced or
even absent iodine staining, whereas normal squamous epithe-
lium is intensely stained by Lugol iodine [5]. Although these un-
stained areas, so-called Lugol voiding lesions, make it more
easy to detect dysplasia or neoplasia, non-dysplastic lesions
such as inflammation can also appear unstained [1]. As a conse-
quence, LCE is highly sensitive but not very specific in the de-
tection of ESCC [1].
In addition, several side effects of LCE have been described,
such as chest discomfort, heartburn, nausea, pulmonary aspira-
tion, and allergic reaction [6, 7]. Another disadvantage for both
the patient and endoscopist is the extended procedure time
[7]. Different concentrations of iodine solution (1% to 3%)
have been used in studies, and patient discomfort seems to de-
pend on the iodine concentration used [8, 9]. A recent random-
ized controlled trial showed that use of 1% iodine solution re-
sulted in less heartburn and retrosternal pain compared to 2%
iodine solution (P=0.02) [8]. In both groups, the color of the
stained esophageal images was similar [8]. LCE with 1% iodine
solution, therefore, is recommended [8].
Early ESCC can also be identified by narrow-band imaging
(NBI) as brown, well-demarcated lesions [6]. This is a real-time
optical chromoendoscopy technique that was first described in
2004 [10]. It visualizes the mucosa and intraepithelial papillary
capillary loop (IPCL) patterns [11]. Although NBI is easy to use
by pressing a button on the endoscope, the device is expensive
and expertise is required [6]. For example, for inexperienced
endoscopists, it might be difficult to distinguish inflammation
from dysplastic lesions using NBI.
Because endoscopic imaging techniques have drastically im-
proved over time and Lugol has several side effects, the ques-
tions arises whether and when Lugol is still necessary.
Before we completely abandon use of Lugol based on cur-
rent knowledge and the evidence presented by Costa-Santos
et al., we have to consider different phases in the endoscopic
treatment of ESSC. There are three important phases that final-
ly lead to endoscopic treatment. First, lesions have to be de-
tected. A second important step is characterization and if
deemed amendable for endoscopic resection, the final impor-
tant step is delineation. All three steps can be done using either
Lugol or NBI. The question arises whether NBI is superior to Lu-
gol in all three steps or there are distinct advantages for each
technique in the separate steps.
1. Lesion detection
Several studies have compared accuracy of LCE with NBI in de-
tection of early ESCC. Wang et al. reported that the combina-
tion of NBI and LCE in detection of ESCC showed the highest
sensitivity (94.7%), compared to LCE (93.0%) and NBI (84.2%)
alone [9]. A recent systematic review and meta-analysis, includ-
ing 12 studies, showed that the sensitivity of NBI and LCE were
comparable (88% vs. 92%) and the specificity was superior with
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NBI (88% vs. 82%, P <0.001) [12]. However, all endoscopies
were performed by expert endoscopists [9, 12]. Therefore, ac-
curacy rates may be lower when performed by a general endos-
copist.
2. Lesion characterization
Esophageal lesions suspected of being dysplastic or neoplastic
are highlighted by LCE as Lugol voiding lesions. Lugol voiding
lesions are present or not, but no further characterization of
these lesions can be made besides gross morphology. As a con-
sequence, it might be difficult to distinguish inflammation
from dysplasia or neoplasia or deeper invasion outside criteria
for endoscopic treatment. In contrast to LCE, IPCLs visible with
NBI can further characterize esophageal lesions. For example,
variety in IPCL shapes, tortuous IPCL, presence of a demarca-
tion line, lesions with brownish dots or brownish epithelium all
were associated with mucosal high-grade neoplasia, according
to Ishihara et al [13]. Based on presence of brownish dots or
brownish epithelium, the sensitivity for detecting neoplasia
was 100% [13].
3. Lesion delineation
In the current issue of this journal, Costa-Santos et al. compar-
ed the effectiveness of NBI and LCE in defining lateral resection
margins before endoscopic resection of ESCC and dysplasia
[14]. Studies on this important step in endoscopic treatment
have not been previously reported. In their study, two groups
of patients with ESCC or dysplasia who underwent en-bloc re-
section were defined: (1) inspection with NBI only; and (2) in-
spection with LCE (with or without NBI). Of 132 included le-
sions, 68 (52%) were inspected with LCE and 64 (48%) with
NBI only. The complete lateral resection rate for invasive carci-
noma did not differ between the two groups; the resection rate
was 90% in the LCE group and 94% in the NBI group (P=0.715).
Also, the lateral resection rate for dysplasia did not differ be-
tween the LCE (65%) and NBI (67%) groups (P =0.813). Costa-
Santos et al. concluded that mucosal inspection with LCE before
endoscopic resection of ESCC and dysplasia was not associated
with an increased complete lateral resection rate compared to
inspection with NBI alone [14].
The results of this study are very interesting and add to our
knowledge about minimal invasive endoscopic treatment of
early cancer. This study supports use of NBI for delineation but
it does not show superiority of NBI versus Lugol. NBI was used in
a recent cohort in which modern endoscopes were used, in con-
trast to the historical LCE cohort in which older endoscopes
were used. NBI was combined with a white light imaging tech-
nique that has dramatically improved over the years, with im-
proved magnification and image resolution. Results with the
combination cannot be separated from use of NBI “alone.” In
contrast, older endoscopes used in the LCE cohort did not dis-
play these superior features. Therefore, the technology in these
two different cohorts with different endoscopes might have in-
fluenced the results of Costa-Santos et al. A fair comparison
would be using both techniques with the same superior endo-
scopes. In addition, the authors did not clearly report on how
many lesions in the LCE group were also inspected with NBI. In-
spection with NBI before Lugol iodine staining may influence on
the definition of lateral resection margins before endoscopic
resection.
For both NBI and LCE, adequate expertise and experience on
the part of the endoscopist is key in detection, characteriza-
tion, and delineation of esophageal lesions. Although NBI
seems superior in terms of specificity and characterization of
lesions, detection of lesions depends on the endoscopist’s ex-
perience. Recognition of specific IPCL patterns is crucial in NBI,
while detection of Lugol voiding lesion by LCE might be easier
for an endoscopist with less experience. Future developments
might very well include artificial intelligence. Computer algo-
rithms can “red flag” or even characterize suspicious areas.
They are already part of video capsule endoscopy and their use
is increasing in colonoscopy screening [15, 16]. In all likelihood,
computer algorithms will make use of these superior imaging
techniques and the role of Lugol will be pushed more to the
background. Until that new era arrives, Lugol can still be a very
useful “red flag” in detection of early squamous neoplasia.
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